Compare EVAX & AMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | AMST |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 3.7M |
| IPO Year | 2020 | 2020 |
| Metric | EVAX | AMST |
|---|---|---|
| Price | $2.90 | $0.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $12.25 | N/A |
| AVG Volume (30 Days) | ★ 129.0K | 28.4K |
| Earning Date | 11-19-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $364,777.00 |
| Revenue This Year | N/A | $19,089.81 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230.24 |
| 52 Week Low | $2.67 | $0.46 |
| 52 Week High | $6.92 | $2.90 |
| Indicator | EVAX | AMST |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 27.04 |
| Support Level | $2.90 | N/A |
| Resistance Level | $3.56 | $1.11 |
| Average True Range (ATR) | 0.31 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 18.80 | 32.63 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Amesite Inc is a technology company focused on building and commercializing AI (artificial intelligence)-powered solutions for the enterprise and for professionals, with particular emphasis on the post-acute healthcare market. It operates through two product lines: NurseMagic and LynkMagic. NurseMagic solutions include a B2B (business-to-business) enterprise application and a B2C (business-to-consumer) solution for individual healthcare professionals. LynkMagic provides enterprise AI solutions for healthcare and related organizations. Its products support documentation, workflow, compliance, oversight, and are designed to improve operational quality and efficiency. It has one single operating and reporting segment, B2C and B2B AI-driven solutions.